The newest Providence head coach spoke to the media on Wednesday about this next chapter.
A new study from Reichman University has found that a short, three-week digital training program, combined with standard drug ...
HAYA Therapeutics has announced full enrolment and dosing of the first cohort in its Phase I clinical trial of HTX-001, a long non-coding ribonucleic acid (lncRNA)-targeting therapy developed for ...